[Optimization of peptide-drug conjugates for targeted tumor therapy].

In case of cancers with high mortality rate and lacking efficient medication there is a huge need of new, innovative treatments. Targeted tumor therapy, a real breakthrough in this field, is based on the concept that the antitumor agent is linked to a targeting molecule (e.g. peptide) specifically recognizing receptors or antigens that are tumor specific or overexpressed by tumor cells. The efficiency of this conjugate can be influenced by several factors. Among these, the structure of the targeting device, the type and number of the antitumor drug, its position in the conjugate and the chemical bonding of the drug to the targeting molecule are all important features that can determine receptor affinity and cellular uptake, and also the release and the cellular localization of the free drug or its active metabolite. Our goal in the framework of the grant NVKP_16-1-2016-0036 was to generate conjugates against cancers with high mortality rate. Through the below described studies, we introduce the course of the research process through which conjugates are optimized in order to develop more efficient drug candidates.